Drug Discovery Featured Articles & Applications

  1. Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections 8/27/2026

    Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

  2. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

    Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

  3. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

    Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

  4. Novel Approach To Cancer Explores Severing Its Genetic Supply Line 8/25/2026

    Gene ablation represents an important and novel approach to treating cancer. One company is focusing on disabling the NRF2 gene to starve cancer cells.

  5. Target Transcription Factor States, Not Pockets 8/21/2026

    Transcription factors expose broad protein–DNA and protein–protein interfaces, contain intrinsically disordered regions, and exchange partners as cellular context changes.

  6. Potency Is Not An Exposure Strategy 8/20/2026

    Potency is measured in an assay; exposure is achieved in an organism. Confusing the two is a category error that still shapes hit selection.

  7. Drugging The tRNA Control System 8/19/2026

    Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. 

  8. Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission 8/18/2026

    EULAR 2026 highlighted growing momentum behind “immune reset,” an approach adapted from oncology that is quickly gaining traction in autoimmune rheumatic diseases.

  9. What The China Biotech Debate Reveals About U.S. Drug Discovery 8/17/2026

    Peter Kolchinsky and Jason Kelly sparred over China’s biotech rise and what it means for U.S. drug discovery, investment, and strategic control.

  10. Closing The Loop Between AI And Experimental Biology 8/17/2026

    We caught up with Rosie Rodriguez, Ph.D., president of growth at Relation, to discuss AI’s place in accelerating discovery